Jim Simons Clearside Biomedical, Inc. Transaction History
Renaissance Technologies LLC
- $62.3 Billion
- Q1 2025
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 554,512 shares of CLSD stock, worth $227,349. This represents 0.0% of its overall portfolio holdings.
Number of Shares
554,512
Previous 721,789
23.18%
Holding current value
$227,349
Previous $721,000
29.26%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11.9MCall Options Held
5.9KPut Options Held
86.6K-
Vanguard Group Inc Valley Forge, PA3.36MShares$1.38 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$900,9663.43% of portfolio
-
Carmignac Gestion Paris, I01.51MShares$618,4200.02% of portfolio
-
Black Rock Inc. New York, NY798KShares$327,2360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA790KShares$324,0520.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $24.7M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...